Pharmaceuticals News

Kailera today announced the completion of enrollment in the KaiNETIC global Phase 3 clinical program.

JADE301 is designed to build on a clinically validated IFN-β mechanism with a differentiated profile designed for infrequent subcutaneous dosingJADE301 demonstrated high-affinity, selective IFN-β...

NASHVILLE, Tenn., Sept. 30, 2026 (GLOBE NEWSWIRE) -- Harrow (Nasdaq: HROW), a leading provider of ophthalmic disease management solutions in North America, today announced that 15 scientific...

DARPA states that the program, if successful, will fundamentally change the Standard of Care for Treatment Resistant Depression. The Military has recognized that current treatments for depression are...

BOSTON, Sept. 30, 2026 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with...

Financing co-led by Novo Holdings and the Ljungström family office, with participation from the originator Helsinn, existing investors Pureos Bioventures, Sound Bioventures, Industrifonden, Flerie,...

R1 Therapeutics expands Series A to $80.5 million to advance global Phase 2b program in hyperphosphatemia

EVerZom successfully completes CTA-enabling preclinical studies of EVerGel™ required to support a clinical trial application

More than 1,600 participants across three published human studies back Calroy Health Sciences' Cartigenix HP with RestorCel joint formulation.

Data from Phase 4 Open-Label, Single-Arm SYNCHRONICITY Trial will be presented in a late-breaking oral presentation during Uveitis Subspecialty Day 2026 Post-hoc analyses of baseline characteristics...